Automate Your Wheel Strategy on QURE
With Tiblio's Option Bot, you can configure your own wheel strategy including QURE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130
Published: April 21, 2025 by: Seeking Alpha
Sentiment: Positive
uniQure's AMT-130 gene therapy for Huntington's Disease shows promising trial data, leading to significant stock price increases and potential for FDA accelerated approval. QURE's stock has seen volatility but has near-term catalysts like BLA submission and 36-month trial data, suggesting potential for immediate further gains. Despite competition from PTC518, AMT-130's effectiveness and one-time treatment advantage could drive substantial revenue and stock price growth.
Read More
uniQure N.V.: A Potential Huntington's Play
Published: February 26, 2025 by: Seeking Alpha
Sentiment: Positive
uniQure's stock surged in December due to positive data around its Huntington's disease candidate AMT-130, clearing the way for potential accelerated FDA approval without another trial. The company's gene therapy Hemgenix, approved for hemophilia B, and three new clinical programs, including AMT-191, AMT-162, and AMT-260, bolster its pipeline. Cost-cutting measures and strategic financing have extended uniQure's operating runway through 2Q28, with significant analyst support and price targets up to $70 a share.
Read More
About uniQure N.V. (QURE)
- IPO Date 2014-02-05
- Website https://www.uniqure.com
- Industry Biotechnology
- CEO Matthew Craig Kapusta
- Employees 209